The study of the marketing strategy of the drug for hyperlipidemia to the taiwan cGMP pharmaceutical company-- The case of C pharmaceutical company
碩士 === 國立中山大學 === 企業管理學系研究所 === 96 === Abstract The rate of hyperlipidemia is increasing due to the change of people’s life style and growing aging problem in recent years. Many studies indicated that hyperlipidemia is the base of atherosclerosis which mainly causes cardiovascular diseases. Therefo...
Main Authors: | Jen-yang Yen, 顏任陽 |
---|---|
Other Authors: | Ying-Chun Li |
Format: | Others |
Language: | zh-TW |
Published: |
2008
|
Online Access: | http://ndltd.ncl.edu.tw/handle/67n5cv |
Similar Items
-
G-Proteins Agonists and NO/cGMP Blockers: Unexplored Frontiers in the Pharmaceutical Industry
by: Paulo Roberto B. Evora -
Characterization of novel rhodopsins with light-regulated cGMP production or cGMP degradation
by: Tian, Yuehui
Published: (2019) -
Studies on Characterization and Tissue Distribution of cGMP-binding cGMP-specific Phosphodiesterase
by: Kotera, Jun
Published: (2014) -
Implementation of PIC / S GMP, Taiwan Pharmaceutical Companies’ Competitive Strategy Strive for International Business
by: Fang, Wan-Ju, et al.
Published: (2015) -
The Viewpoint of cGMP on Software Specification
by: YU YUAN CHANG, et al.
Published: (2005)